Bioavailability of two clodronate formulations

British Journal of Hospital Medicine

Volumn 56, Issue 5, 1996, Pages 231-233

  Lapham, G ^a,c   Aranko, K ^a   Hanhijarvi H ^b   Humphreys, D M ^a  

^a Medical Operations Group III

^b BOEHRINGER INGELHEIM LTD   (United Kingdom)

^c Research and Development   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CLODRONIC ACID;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MONITORING; FEMALE; HUMAN; MALE; MICROCAPSULE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, NON-NARCOTIC; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CLODRONIC ACID; CROSS-OVER STUDIES; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0030568749     PISSN: 00071064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Aranko K, Humphreys M, Drake J, Lawton W A (1995) Letter to the Editor. Bone 16: 275-6
2. 2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4: 163-8
3. Elomaa I, Blomqvist C, Gröhn P et al (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet i: 146-9
4. Investigation of Bioavailability and Bioequivalence (1992) Rules Governing Medicinal Products in the European Community III: 149-68
5. Iveson TJ, Powles TJ, Tidy A et al (1995) Clpdronate decreases the incidence of bone metastases in patients with advanced or metastatic breast cancer but no clinical evidence of bone metastases. Br J Cancer 71 (Suppl XXIV): 15
6. Kanis JA, O'Rourke N, McCloskey EV (1994) Consequences of neoplasia induced bone resorption and the use of clodronate. Int J Oncol 5: 713-31
7. Laakso M, Lahtinen R, Virkkunen P, Elomma I (1994) Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol 87: 725-9
8. Lahtinen R, Laasko M, Palva I, Virkkunen P, Elomma I (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049-52
9. McCloskey EV (1994) Oral clodronate reduces skeletal morbidity in multiple myelomatosis. Vlth MRC Myelomatosis Trial. Bone Miner 25 (Suppl 1): S80
10. McCloskey EV, Ashley S, Paterson AHG, Powles T, Kanis JA (1993) Compliance and efficacy of clodronate in metastatic skeletal disease in breast cancer. J Bone Miner Res 8 (Suppl 1): Abstract 680
11. Metropolitan Life Insurance Company (1983) Heaght and mass tables. Statist Bull Metrop Life found 64(1): 4
12. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis J (1995) Double-blind, placebo-controlled, dose response trial of oral clodronate in patients with bone metastases. J Clin Oncol 13: 929-34
13. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
14. Saha H, Castre-Kortekangas P, Ojanen S et al (1994) Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 9: 1953-8